Clicky

  • Login
  • Register
  • Submit Your Content
  • Contact Us
Friday, October 17, 2025
World Tribune
No Result
View All Result
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food
Submit
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food
No Result
View All Result
World Tribune
No Result
View All Result

Eli Lilly weight loss drug cuts risk of developing diabetes in trial

August 20, 2024
in News
Reading Time: 3 mins read
A A
Eli Lilly weight loss drug cuts risk of developing diabetes in trial
0
SHARES
ShareShareShareShareShare

Eli Lilly weight loss drug cuts risk of developing diabetes in trial

Eli Lilly’s highly popular weight loss drug reduced the risk of developing Type 2 diabetes by 94% in obese or overweight adults with prediabetes compared with a placebo, according to initial results from a long-term study released Tuesday. 

The late-stage trial on tirzepatide, the active ingredient in the company’s weight loss injection Zepbound and diabetes drug Mounjaro, also found that patients experienced sustained weight loss over the roughly three-year treatment period. Adults on the highest weekly dose of the drug saw a 22.9% decrease in body weight on average after 176 weeks, compared with 2.1% for those who received a placebo. 

The results suggest that Eli Lilly’s treatment could meaningfully delay a potential diagnosis for people with prediabetes, or those with blood sugar levels that are higher than normal but not high enough to be classified as Type 2 diabetes. 

More than 1 in 3 Americans have prediabetes, according to the latest government data, which health experts say can be reversed with lifestyle changes such as diet and exercise. People who are overweight or have obesity are at a higher risk for prediabetes. 

The new data also shows the potential long-term health benefits of taking a buzzy class of obesity and diabetes medications called GLP-1s, which mimic hormones produced in the gut to tamp down appetite and regulate blood sugar. As Eli Lilly’s Zepbound and Mounjaro and injections from rival Novo Nordisk have skyrocketed in popularity over the last two years, the companies have raced to study other clinical uses for their drugs.

“Obesity is a chronic disease that puts nearly 900 million adults worldwide at an increased risk of other complications such as Type 2 diabetes,” Dr. Jeff Emmick, senior vice president of product development at Eli Lilly, said in a statement. “These data reinforce the potential clinical benefits of long-term therapy for people living with obesity and pre-diabetes.”

Eli Lilly tested tirzepatide in more than 1,000 adults over 176 weeks in the phase three trial, followed by a 17-week period where patients stopped treatment. It is the longest completed study on the drug to date, according to the company. 

More CNBC health coverage

The drugmaker will submit the latest results to a peer-reviewed journal and present them at an upcoming medical conference in November. Eli Lilly published 72-week weight loss results on a larger group of patients from the same trial, called SUMOUNT-1, back in 2022. 

Patients in the trial who stopped taking tirzepatide during the 17 weeks began to regain weight and saw an increase in progression to diabetes. But those participants still had an 88% lower risk of developing diabetes compared with a placebo, according to the latest phase three results.

The safety data on tirzepatide during the trial was consistent with previous studies on the drug, according to Eli Lilly. The most common side effects were gastrointestinal, such as diarrhea, nausea, constipation and vomiting, and were generally mild to moderate in severity.

Eli Lilly’s Zepbound works by imitating two naturally produced gut hormones called GLP-1 and GIP. 

GLP helps reduce food intake and appetite. GIP, which also suppresses appetite, may also improve how the body breaks down sugar and fat.

Don’t miss these insights from CNBC PRO

Watch CNBC's full interview with Eli Lilly CEO David Ricks

Credit: Source link

READ ALSO

Zelensky Seeks More Weapons as Trump Plans Putin Meeting

Bad loans by regional banks should concern us all

ShareTweetSendSharePin
Previous Post

‘Troubling’ part of Sam Ponder’s ESPN firing

Next Post

Apple’s 13-inch iPad Air M2 drops to a record-low price

Related Posts

Zelensky Seeks More Weapons as Trump Plans Putin Meeting
News

Zelensky Seeks More Weapons as Trump Plans Putin Meeting

October 17, 2025
Bad loans by regional banks should concern us all
News

Bad loans by regional banks should concern us all

October 17, 2025
Kenyan Police Fire on Mourners at Raila Odinga Memorial
News

Kenyan Police Fire on Mourners at Raila Odinga Memorial

October 17, 2025
Trump Considers Ground Strikes in Venezuela
News

Trump Considers Ground Strikes in Venezuela

October 16, 2025
UPI’s global push seems an economic strategy
News

UPI’s global push seems an economic strategy

October 16, 2025
China’s Communist Party meets for its next five-year plan
News

China’s Communist Party meets for its next five-year plan

October 16, 2025
Next Post
Apple’s 13-inch iPad Air M2 drops to a record-low price

Apple's 13-inch iPad Air M2 drops to a record-low price

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

What's New Here!

What makes a good NFL backup QB — and our ranking of all 32

What makes a good NFL backup QB — and our ranking of all 32

September 19, 2025
CrowdStrike pops 13% on upbeat long-term guidance at investor day

CrowdStrike pops 13% on upbeat long-term guidance at investor day

September 19, 2025
Packers’ undefeated talk didn’t sit well with Matt LaFleur

Packers’ undefeated talk didn’t sit well with Matt LaFleur

September 23, 2025
Asia markets reverse earlier losses as investors sell tech names on Wall Street

Asia markets reverse earlier losses as investors sell tech names on Wall Street

September 25, 2025
Why Beijing is freezing Nvidia’s access to the Chinese market

Why Beijing is freezing Nvidia’s access to the Chinese market

September 18, 2025
Yankees can’t fear wild-card series with tormenting Astros

Yankees can’t fear wild-card series with tormenting Astros

September 18, 2025
Nothing’s Ear 3 buds have a walkie-talkie style ‘super mic’

Nothing’s Ear 3 buds have a walkie-talkie style ‘super mic’

September 18, 2025

About

World Tribune is an online news portal that shares the latest news on world, business, health, tech, sports, and related topics.

Follow us

Recent Posts

  • Zelensky Seeks More Weapons as Trump Plans Putin Meeting
  • Dodgers’ Michael Conforto making best of postseason letdown
  • Bengals’ Joe Flacco outlasts Steelers’ Aaron Rodgers in NFL instant classic
  • Bad loans by regional banks should concern us all

Newslatter

Loading
  • Submit Your Content
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • DMCA

© 2024 World Tribune - All Rights Reserved!

No Result
View All Result
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food

© 2024 World Tribune - All Rights Reserved!

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In